SCHEMBL20440773

SCHEMBL20440773

O=c1oc2ccccc2cc1S(=O)(=O)Nc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.60
CA9 Q16790 3/20 0.60
CA1 P00915 2/20 0.60
CA2 P00918 1/20 0.60
GPR27 Q9NS67 1/20 0.60
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
MAOB P27338 5/20 0.50
MAOA P21397 2/20 0.50
F12 P00748 1/20 0.50
NT5E P21589 1/20 0.48
RAB9A P51151 2/20 0.47
ERAP1 Q9NZ08 2/20 0.47
IL1RN P18510 1/20 0.47
KEAP1 Q14145 1/20 0.47
CA3 P07451 1/20 0.46
TSHR P16473 1/20 0.46
CA4 P22748 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5428747 0.86 GPR27 (0.56) CA12CA9CA1CA2GPR27
SCHEMBL5616885 0.85 PKM (0.57) CA12CA9CA1CA2GPR27
SCHEMBL831190 0.81 CA12 (0.64) CA12CA9CA1CA2GPR27
SCHEMBL20440772 0.79 TP53 (0.61) GPR27ALDH1A1KDM4EMAOBHPGD
SCHEMBL830181 0.79 CA12 (0.74) CA12CA9CA1CA2ALDH1A1
SCHEMBL20435590 0.76 KDM4E (0.78) CA12CA9CA1CA2ALDH1A1
SCHEMBL830136 0.76 CA1 (1.00) CA12CA9CA1CA2ALDH1A1
SCHEMBL22273887 0.76 CA12 (0.70) CA12CA9CA1CA2ALDH1A1
SCHEMBL1047082 0.76 CA12 (0.70) CA12CA9CA1CA2ALDH1A1
SCHEMBL831132 0.76 CA12 (0.70) CA12CA9CA1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity Zander Biologics, Inc (US) 2022-07-05 US disclosed
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans KCL THERAPEUTICS, INC. (US) 2022-05-10 US disclosed
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS Zander Therapeutics, Inc. (US) 2020-03-05 US disclosed
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals Zander Therapeutics, Inc. (US) 2019-11-12 US disclosed
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals Zander Therapeutics, Inc. 2019-02-21 US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 CA12 4294/4885CA9 4839/4885CA1 4707/4885
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 CA12 4297/4885CA9 4847/4885CA1 4626/4885
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals NR4A2, NR2C2, NR0B2 CA12 4297/4885CA9 4847/4885CA1 4626/4885
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans NR4A2, NR2C2, NR0B2 CA12 4294/4885CA9 4839/4885CA1 4707/4885
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity NR4A2, NR2C2, NR2F2 CA12 4080/4885CA9 4834/4885CA1 4515/4885
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals NR4A2, NR2C2, NR0B2 CA12 4297/4885CA9 4847/4885CA1 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.